DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Lawitz E, Freilich B, Link J. et al.
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus.

Journal of viral hepatitis 2015;
22: 1011-1019

Download Bibliographical Data

Access:
Access: